Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

High induction doses of risankizumab — at double and quadruple the approved 150 mg dose — produced rapid and durable skin clearance in patients with moderate-to-severe plaque psoriasis while ...

A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...

AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor, risankizumab ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...

A new analysis highlights differential long-term drug survival of commonly used biologics in psoriasis to guide treatment ...

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...

Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients. A recently approved injectable eczema drug provides quick ...